Latest News
Immix Biopharma, Inc.
- Morgan Stanley initiates Immix Biopharma stock with overweight rating
- Immix Biopharma, Inc. (IMMX) Stock Price Prediction for 2026, 2030-2040
- Immix’s NXC-201 achieves 89% complete response rate in AL amyloidosis trial
- Immix Bio offering to raise USD 125m after 89% CR rate for BCMA CAR T in amyloidosis
- Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
- Citizens reiterates Immix Biopharma stock rating on trial data
- Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
- Form 8K Immix Biopharma Inc For: 29 September By Investing.com
- Immix Biopharma prices $125M stock offering
- Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
- Immix Biopharma Announces 89% Complete Response Rate at
- Immix Biopharma raises $130M in stock offering for CAR-T amyloidosis therapy
Headlines from the last 30 days, linking to the original publishers. See all market news →